References
- World Health Organisation. The world health report 2002. Reducing risks, promoting healthy life. Geneva: The World Health Organisation, 2002
- Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research Taskforce. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ. 2008;178:1429-35
- Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research Taskforce. Mortality among patients with hypertension from 1995 to 2005: a population-based study. CMAJ. 2008;178:1436-40
- Leenen FHH, Dumais J, McInnis NH, et al. Results of the Ontario Survey on the Prevalence and Control of Hypertension. CMAJ 2008;178:1441-9
- Moser M, Gifford RW Jr, Handler J. Isolated systolic hypertension: an update. J Clin Hypertens 2000;2:215-21
- Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
- Khan NA, Hemmelgarn B, Padwal R, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can J Cardiol 2007;23:539-50
- Mavik (trandolapril), Product Monograph. Montreal: Abbott Laboratories, 2001
- Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994;48:71-90
- Omboni S, Ravogli A, Villani A, et al. Permanent blood pressure control over the 24 h by trandolapril. Am J Hypertens 1995;8:71S-4S
- Dutrey-Dupagne C, Girard A, Ulmann A, et al. Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension. Clin Auton Res 1991;1:303-7
- Tytus R, Burgess E, Assouline L, et al. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Clin Ther 2007;29:305-15
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002;48:206-8
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice, E6. Geneva: World Health Organization, 1996
- Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72
- Neutel JM, Gilderman LI. Hypertension control in the elderly. J Clin Hypertens (Greenwich) 2008;10:33-9
- Franklin SS. Hypertension in older people: part 2. J Clin Hypertens (Greenwich) 2006;7:521-5
- Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med 2008;121:179-84
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
- Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
- Gojanovic B, Feihl F, Liaudet L, et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 2008;91:1-9
- Matchar DB, McCrory DS, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29
- Nelson MR, Reid CM, Ryan P, et al. Self-reported adherence with medication and cardiovascular disease outcomes in the second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006;185:487-9
- Simons LA, Ortiz O, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. MJA 2008;188:224-7